Entheon Biomedical Corp. (ENTBF)
| Previous Close | 0.2200 |
| Open | 0.2138 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1907 - 0.2189 |
| 52 Week Range | 0.1907 - 1.5000 |
| Volume | |
| Avg. Volume | 65,198 |
| Market Cap | 13.042M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1690 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced the submission of the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the Assessment
- Baystreet
Stocks in play: Entheon Biomedical Corp.
Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, ...
- Newsfile
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel
Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased
